Chris E. Holmes

Biography

Dr. Holmes has received her PhD University of Virginia Graduate School of Arts and Sciences, Department of Chemistry. Currently, she is Research Professor, Department of Psychiatry in university of vermont. She has successfully completed his Administrative responsibilities as Professor. Her research focuses on developing evidence-based clinical interventions to reduce venous and arterial thrombosis in patients with cancer through the optimum utilization of anticoagulation and anti-platelet therapy. The most recent clinical initiative is a novel quality-health services research study that is designed to capture thrombosis and bleeding outcomes in cancer outpatients initiating therapy.

Research Interest

Dr. Holmes’ research focuses on developing evidence-based clinical interventions to reduce venous and arterial thrombosis in patients with cancer through the optimum utilization of anticoagulation and anti-platelet therapy. The most recent clinical initiative is a novel quality-health services research study that is designed to capture thrombosis and bleeding outcomes in cancer outpatients initiating therapy. The program, Venous ThromboEmbolism Prevention in the Ambulatory Cancer Clinic (termed VTEPACC), is currently assessing a novel multidisciplinary approach to venous thromboembolism (VTE) prevention which includes patient center, personalized decision making. Additional collaborative and ongoing studies include a clinical trial using apixaban for VTE prophylaxis in patients with malignant glioma and an assessment of thrombosis risk associated with immunotherapy in metastatic cancer. In the area of translational science, Dr. Holmes’ group was the first to report that tumor genetics (KRAS status) is associated with VTE risk in metastatic colon cancer - an observation that offers a potentially novel future approach to VTE risk stratification. In addition, the lab has demonstrated distinct changes in platelet phenotype due to cancer and its treatment that result in the need for lower doses of anti-platelets drugs to successfully inhibit platelet function- an observation that has clinical significance for safe dosing of anti-platelet therapy in cancer patients.